The impact of low-energy total diet replacement with behavioural support for remission of type 2 diabetes on disordered eating (ARIADNE): Protocol for a non-inferiority randomised controlled trial

IF 2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
E. Tsompanaki , P. Aveyard , R.J. Park , D.A. Koutoukidis
{"title":"The impact of low-energy total diet replacement with behavioural support for remission of type 2 diabetes on disordered eating (ARIADNE): Protocol for a non-inferiority randomised controlled trial","authors":"E. Tsompanaki ,&nbsp;P. Aveyard ,&nbsp;R.J. Park ,&nbsp;D.A. Koutoukidis","doi":"10.1016/j.cct.2024.107542","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>The National Health Service (NHS) in England is currently piloting a weight loss programme for remission of newly diagnosed type 2 diabetes (T2D), where participants replace all food with low-energy nutritionally complete formula products for 12 weeks (total diet replacement, TDR) and receive behavioural support. In a clinical trial, this programme led to remission in nearly half the participants. However, this weight loss programme might also worsen disordered eating and prompt eating disorders in susceptible people. We aim to investigate if the TDR programme is non-inferior to standard care in terms of disordered eating in susceptible individuals.</p></div><div><h3>Methods</h3><p>Fifty six people with newly diagnosed T2D, BMI ≥ 27 kg/m<sup>2</sup>, and medium to high scores of disordered eating based on the Eating Disorders Examination questionnaire (EDE-Q) will be randomised 1:1 to TDR receiving remote weekly/bi-weekly dietetic support or standard care. Participants will be re-assessed remotely at 1, 3, 4, 6, and 12 months. The primary outcome will be the between-group difference in the score of the EDE-Q. If the sample size can be expanded to 150, we will reduce the non-inferiority boundary. Weight, glycated haemoglobin (HbA1c), impairment from disordered eating, and distress will be secondary outcomes. Using the recorded consultations, we will evaluate the process in observed changes in eating behaviour and disordered eating.</p></div><div><h3>Conclusions</h3><p>If TDR for T2D remission is deemed non-inferior to standard care, more people may enrol and benefit from T2D remission. If TDR exacerbates disordered eating, screening may reduce unintended harm.</p><p><strong>Trial Registration:</strong> <span>NCT05744232</span><svg><path></path></svg> (<span>ClinicalTrials.gov</span><svg><path></path></svg>, prospectively registered).</p></div>","PeriodicalId":10636,"journal":{"name":"Contemporary clinical trials","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary clinical trials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1551714424001253","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

The National Health Service (NHS) in England is currently piloting a weight loss programme for remission of newly diagnosed type 2 diabetes (T2D), where participants replace all food with low-energy nutritionally complete formula products for 12 weeks (total diet replacement, TDR) and receive behavioural support. In a clinical trial, this programme led to remission in nearly half the participants. However, this weight loss programme might also worsen disordered eating and prompt eating disorders in susceptible people. We aim to investigate if the TDR programme is non-inferior to standard care in terms of disordered eating in susceptible individuals.

Methods

Fifty six people with newly diagnosed T2D, BMI ≥ 27 kg/m2, and medium to high scores of disordered eating based on the Eating Disorders Examination questionnaire (EDE-Q) will be randomised 1:1 to TDR receiving remote weekly/bi-weekly dietetic support or standard care. Participants will be re-assessed remotely at 1, 3, 4, 6, and 12 months. The primary outcome will be the between-group difference in the score of the EDE-Q. If the sample size can be expanded to 150, we will reduce the non-inferiority boundary. Weight, glycated haemoglobin (HbA1c), impairment from disordered eating, and distress will be secondary outcomes. Using the recorded consultations, we will evaluate the process in observed changes in eating behaviour and disordered eating.

Conclusions

If TDR for T2D remission is deemed non-inferior to standard care, more people may enrol and benefit from T2D remission. If TDR exacerbates disordered eating, screening may reduce unintended harm.

Trial Registration: NCT05744232 (ClinicalTrials.gov, prospectively registered).

低能量全膳食替代与行为支持对缓解 2 型糖尿病饮食紊乱的影响 (ARIADNE):非劣效随机对照试验方案
导言:英国国家医疗服务系统(NHS)目前正在试行一项减肥计划,旨在缓解新诊断出的 2 型糖尿病(T2D)患者的病情,参与者将在 12 周内用低能量营养全面的配方产品替代所有食物(总饮食替代,TDR),并接受行为支持。在一项临床试验中,近一半参与者的病情得到了缓解。然而,这种减肥计划也可能会加重易感人群的饮食紊乱,并引发饮食失调。我们的目的是调查在易感人群的进食紊乱方面,TDR 计划是否不劣于标准护理。方法将新诊断为 T2D、体重指数(BMI)≥ 27 kg/m2、根据进食紊乱检查问卷(EDE-Q)有中高分进食紊乱的 56 名患者按 1:1 随机分配到接受每周/两周一次远程营养支持的 TDR 或标准护理中。参与者将在 1、3、4、6 和 12 个月时接受远程重新评估。主要结果将是 EDE-Q 评分的组间差异。如果样本量能扩大到 150 个,我们将降低非劣效性边界。体重、糖化血红蛋白 (HbA1c)、饮食失调造成的损伤和痛苦将是次要结果。结论如果治疗 T2D 缓解的 TDR 被认为不劣于标准治疗,那么可能会有更多的人参加并从 T2D 缓解中获益。如果TDR加剧了饮食紊乱,筛查可能会减少意外伤害:NCT05744232(ClinicalTrials.gov,前瞻性注册)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.50%
发文量
281
审稿时长
44 days
期刊介绍: Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信